Eaton Vance Management Neogenomics Inc Transaction History

Eaton Vance Management

$67.5 Billion
Q3 2022

A detailed history of Eaton Vance Management transactions in Neogenomics Inc stock. As of the latest transaction made, Eaton Vance Management holds 410,828 shares of NEO stock, worth $5.58 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

410,828

Previous 411,086 0.06%

Holding current value

$5.58 Million

Previous $3.35 Million 5.58%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.86 - $12.91 $2,027 - $3,330	-258 Reduced 0.06%	410,828 $3.54 Million
Q2 2022 Aug 15, 2022	SELL	$7.06 - $13.97 $183,955 - $364,002	-26,056 Reduced 5.96%	411,086 $3.35 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $35.28 $293,811 - $853,140	24,182 Added 5.86%	437,142 $5.31 Million
Q4 2021 Feb 14, 2022	SELL	$30.49 - $48.49 $18,690 - $29,724	-613 Reduced 0.15%	412,960 $14 Million
Q3 2021 Nov 15, 2021	BUY	$41.66 - $52.52 $1.71 Million - $2.16 Million	41,138 Added 11.05%	413,573 $19.8 Million

Q2 2021 Aug 16, 2021	BUY	$36.62 - $51.69 $4.35 Million - $6.13 Million	118,688 Added 46.77%	372,435 $16.8 Million
Q1 2021 May 17, 2021	BUY	$41.56 - $59.88 $71,441 - $102,933	1,719 Added 0.68%	253,747 $12.2 Million
Q4 2020 Feb 12, 2021	BUY	$36.08 - $56.47 $1.38 Million - $2.16 Million	38,327 Added 17.93%	252,028 $13.6 Million
Q3 2020 Nov 13, 2020	BUY	$33.26 - $40.48 $698 - $850	21 Added 0.01%	213,701 $7.88 Million
Q2 2020 Aug 13, 2020	SELL	$24.21 - $31.02 $193 - $248	-8 Reduced -0.0%	213,680 $6.62 Million
Q1 2020 May 14, 2020	BUY	$20.5 - $34.53 $4.38 Million - $7.38 Million	213,688 New	213,688 $5.9 Million

Others Institutions Holding NEO

# of Institutions

282

Shares Held

128M

Call Options Held

1.13M

Put Options Held

232K

View Full List

About NEOGENOMICS INC

Ticker NEO
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 125,796,000
Market Cap $1.71B
Description
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...

More about NEO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Account

Eaton Vance Management Neogenomics Inc Transaction History